cystic fibrosis transmembrane conductance regulator

Overview

The cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-binding cassette (ABC) transporter-class ion channel encoded by the CFTR gene (Wikidata: Q420470) on human chromosome 7q31.2. The protein functions primarily as a regulated chloride and bicarbonate anion channel expressed at the apical surface of epithelial cells lining the airways, intestine, pancreatic ducts, sweat glands, and reproductive tract. CFTR channel gating is controlled by phosphorylation of its regulatory (R) domain and by ATP binding and hydrolysis at its two nucleotide-binding domains. When CFTR function is lost or severely diminished — due to any of more than 2,000 identified pathogenic variants in the CFTR gene — chloride transport across epithelial membranes is disrupted, leading to the accumulation of abnormally thick, dehydrated mucus and the multisystem disease known as cystic fibrosis (CF).

CF is one of the most common life-limiting autosomal recessive disorders in populations of Northern European descent, affecting the respiratory system most critically through cycles of mucus obstruction, bacterial infection, and progressive inflammation, while also causing pancreatic exocrine insufficiency, intestinal dysmotility, hepatobiliary disease, and male infertility. The severity and organ distribution of disease depend heavily on the specific class of CFTR mutation carried by an individual. Class I mutations introduce premature stop codons (nonsense mutations) that prevent full-length protein synthesis; Class II mutations (most notably F508del, the most prevalent CF allele) cause misfolding and premature proteasomal degradation; Class III mutations impair channel gating; and Classes IV–VI affect conductance, expression levels, or protein stability. This mutation-class framework has become central to the development and clinical stratification of CFTR-targeting pharmacotherapies, broadly termed CFTR modulators.

Recent Publications Summary

Recent studies on cystic fibrosis transmembrane conductance regulator (CFTR) have focused heavily on improving functional assessment of the channel and on refining CFTR-directed therapies. A flexible electrochemical sensor modified with silver nanoparticles was developed to quantify chloride ions in cystic fibrosis epithelial cell models, with the platform able to distinguish chloride levels in cultures carrying different CFTR pathogenic variants and to detect the effect of elexacaftor/tezacaftor/ivacaftor (ETI) treatment versus untreated samples 42240701Jun. In parallel, a 24-month real-world study examined genotype-dependent biochemical responses to ETI in children with cystic fibrosis using sweat chloride concentration as a biomarker of CFTR function 42067070May. Another study compared the long-term effects of different CFTR modulators in people with cystic fibrosis, reflecting ongoing efforts to understand how these agents shape clinical outcomes over time 42206906May.

Several publications addressed strategies to restore CFTR function in difficult-to-treat mutations. One study developed an adenine base editing approach to correct the prevalent 1717-1G>A splicing mutation, achieving up to 30% editing in a cellular model and demonstrating repair in airway epithelial cells and intestinal organoids derived from people with cystic fibrosis 42018671Apr. A separate precision-editing study engineered APOBEC3G base editor variants with improved targeting scope and precision, and validated them by installing and correcting cystic fibrosis-causing mutations; in human bronchial epithelial cells, this editing modulated CFTR mRNA levels, protein expression, and channel function 41536070Jan. For nonsense mutations, a triple combination of ELX-02, VX-809, and CC-90009 produced a modest increase in CFTR function in G542X airway epithelia, but efficacy was markedly enhanced under inflammatory conditions induced by IL-4 or by IL-17A/TNF-α 41381228Dec.

Other work explored how CFTR modulators affect biology beyond the airway and how drug design can improve target engagement. Mass-spectrometry-based proteomics of plasma and serum from people with cystic fibrosis treated with lumacaftor/ivacaftor or ETI identified inflammation- and metabolism-related signatures, with ETI producing broader and more consistent shifts toward profiles seen in healthy individuals 41928517Apr. At the medicinal chemistry level, systematic modification of the lipophilic substituent of the CFTR potentiator ABBV-974 yielded an analog with markedly increased functional residence time, suggesting that membrane residence can be leveraged to design longer-acting potentiators 42046515Apr. Together, these studies highlight continued progress in measuring CFTR activity, correcting pathogenic variants, and optimizing modulators for more durable and comprehensive therapeutic effects 42240701Jun42067070May42018671Apr41536070Jan41381228Dec41928517Apr42046515Apr.

Preventive care remains an important complement to CFTR-directed treatment. In children with cystic fibrosis followed at the Regional Reference Centre of Tuscany, vaccination coverage was high for mandatory immunizations, including Haemophilus influenzae type b and Bordetella pertussis, while influenza vaccination peaked during the COVID-19 pandemic and then declined afterward; pneumococcal vaccination coverage was also reported as high 42373575Jun. This underscores that, despite advances in CFTR modulators, infection prevention remains a key component of care in cystic fibrosis 42373575Jun.

What Changes, What Holds

1. Functional readouts of CFTR activity are becoming more precise and clinically informative
METHOD Flexible chloride-sensing platforms and longitudinal sweat chloride tracking do not alter the established biology of CFTR, but they improve how CFTR function is measured in cells and in treated patients. That makes them useful for distinguishing variant-specific residual activity and for monitoring response to elexacaftor/tezacaftor/ivacaftor, without changing the baseline account of CFTR as an epithelial anion channel or of modulators as its therapies 42240701Jun42067070May.

2. Base editing is extending CFTR correction beyond modulation, but the evidence remains preclinical
NEW DIRECTION Adenine and APOBEC3G editing approaches move beyond the Overview’s mutation-class framework and CFTR modulators by aiming to repair pathogenic alleles directly, including splicing and nonsense defects that are often hard to treat. That does not overturn the baseline, but it adds a gene-correction route that could eventually complement or bypass pharmacologic rescue; the current support is cellular and organoid-level, so durable efficacy and safety in patients still need to be shown 42018671Apr41536070Jan41381228Dec.

3. CFTR modulators may reshape systemic biology, and longer-acting potentiators are now a design goal
NEW DIRECTION Proteomic shifts in blood suggest that CFTR-directed therapy can influence inflammation and metabolism beyond the airway, which broadens the entity’s therapeutic footprint without contradicting the established respiratory and epithelial disease model 41928517Apr. In parallel, the residence-time work on ABBV-974 indicates that drug design is moving toward more durable channel engagement, a refinement of modulator pharmacology rather than a new mechanism 42046515Apr.

4. Infection prevention remains necessary despite effective CFTR-directed therapy
REINFORCES High vaccine coverage in children with cystic fibrosis supports, rather than challenges, the baseline view that CF remains a multisystem condition requiring ongoing supportive care even as modulators improve underlying channel function 42373575Jun. The finding does not change CFTR biology or treatment strategy; it simply underscores that infection prevention still belongs alongside CFTR-targeted therapy in routine management.

Overview update candidates: direct CFTR correction by base editing; systemic proteomic effects of modulators; longer functional residence time as a modulator design principle.